Form 4: Benitec CEO Banks Granted 450,000 Stock Options

Benitec Biopharma Inc. CEO Jerel A. Banks was granted 450,000 stock options with an exercise price of $13.53, vesting quarterly starting March 2026.

Summary

• Jerel A. Banks, the Chief Executive Officer and a Director of Benitec Biopharma Inc. (BNTC), was granted 450,000 derivative securities in the form of stock options.
• The transaction date for this grant was November 18, 2025.
• Each option has an exercise price of $13.53.
• The options represent the right to buy 450,000 shares of Common Stock.
• The options will expire on November 18, 2035.
• Vesting for these stock options will occur in 16 substantially equal quarterly installments, commencing on March 31, 2026.
• Following this transaction, Jerel A. Banks beneficially owns 450,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is generally a positive signal, as it aligns management's interests with shareholders and provides a long-term incentive for performance. It is a standard compensation practice.

Positives

• The grant of stock options to the CEO aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The significant number of options (450,000) indicates a substantial equity stake for the CEO, reinforcing commitment to the company's future.

Negatives

• The exercise of these options in the future could lead to dilution for existing shareholders, although this is a standard aspect of equity compensation plans.

Future Outlook

The vesting schedule of the stock options, extending over 16 quarterly installments commencing in March 2026, indicates a long-term incentive structure designed to align the CEO's performance with future company growth and shareholder value creation.

Industry Context

The grant of stock options to a Chief Executive Officer is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages. This approach aims to attract, retain, and motivate top talent by linking their personal financial success to the company's long-term stock performance.

Comparison to Industry Standards

• Granting stock options as a form of executive compensation is a standard practice across various industries, including biotechnology, to align management incentives with shareholder interests.
• The vesting schedule over multiple years is typical for long-term incentive plans, promoting sustained performance rather than short-term gains.

Related Party Transactions

• The grant of 450,000 stock options to Jerel A. Banks, the Chief Executive Officer and a Director, constitutes a related party transaction as it involves compensation from the company to an executive officer and director.

Stakeholder Impact

• Shareholders: The grant aims to align the CEO's interests with shareholder value creation, potentially leading to improved long-term performance. However, future exercise could lead to dilution.
• Employees: May signal stability and confidence in leadership, potentially boosting morale.
• Management: Provides a significant long-term incentive for the CEO to drive company growth and achieve strategic objectives.

Next Steps

• The stock options will begin vesting in 16 substantially equal quarterly installments starting March 31, 2026.

Key Dates

Keywords

Benitec Biopharma, BNTC, stock options, executive compensation, insider transaction, CEO, equity grant, Form 4